The Mpathy Medical acquisition will expand the Coloplast female health portfolio of product technologies and surgical solutions for female stress urinary incontinence and pelvic organ prolapse.

The acquisition allows Coloplast to build a strong market presence within the highly competitive $500m, US and EU female pelvic health specialties market.

Coloplast will combine the two companies’ complementary products into the Coloplast Surgical Urology division.

Coloplast Surgical Urology global vice president Dave Amerson said that they will leverage the strengths and best practices of both companies, which will give them customers access to an even stronger product portfolio and innovative solutions for restoring female pelvic health.